Eli Lilly Raises 2024 Guidance, Focuses on New Oral Obesity Drug

Eli Lilly has revised its 2024 financial guidance upward. The company raised its annual revenue forecast to $46.6-$47.8 billion from the previous range of $45.4-$46.6 billion, driven by growing interest in its newly developed oral obesity drug. This revision reflects the company's strong performance in obesity and diabetes treatments. Eli Lilly's new oral obesity pill is drawing attention as an alternative to existing injectable therapies. The company reported promising results from clinical trials, showing significant effects on weight loss. Analysts believe this product has substantial potential in the obesity market and could strengthen Eli Lilly's leadership in this area. The company's robust financial outlook is supported by rising sales of popular drugs such as Mounjaro and Zepbound. Eli Lilly expects continued demand growth for these products. Additionally, the launch of the new oral obesity pill is anticipated to drive further revenue growth. Investors remain confident in Eli Lilly due to its innovative drug portfolio and advancements in obesity treatments. However, factors such as market competition and regulatory risks could impact the company's future performance. This is not investment advice.